Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial evaluating Vutrisiran for Stargardt Disease

Next Previous
X
Search
Trial Profile

A phase III trial evaluating Vutrisiran for Stargardt Disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vutrisiran (Primary)
  • Indications Stargardt disease
  • Focus Therapeutic Use
  • Sponsors Alnylam Pharmaceuticals

    • Most Recent Events

    • 27 Oct 2022 According to an Alnylam Pharmaceuticals media release, the company announces that it will not initiate this study in late 2022, as previously guided, as it continues to evaluate the impact of the Inflation Reduction Act.
    • 06 Dec 2021 New trial record
    • 19 Nov 2021 According to an Alnylam Pharmaceuticals media release, company plans to initiate this study in late 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top